Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
- Status
- TERMINATED
- Phase
- PHASE2
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE3
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Abemaciclib + Pembrolizumab In Glioblastoma
- Status
- WITHDRAWN
- Phase
- PHASE2
Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.
- Status
- UNKNOWN
- Phase
- PHASE2
Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Microbiome Immunotherapy Toxicity and Response Evaluation
- Status
- UNKNOWN
- Phase
- N/A
A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2